JP2024063143A5 - - Google Patents
Info
- Publication number
- JP2024063143A5 JP2024063143A5 JP2024030700A JP2024030700A JP2024063143A5 JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5 JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- composition
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US62/678,025 | 2018-05-30 | ||
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US62/726,612 | 2018-09-04 | ||
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| US62/822,336 | 2019-03-22 | ||
| GC2019/37661 | 2019-05-28 | ||
| GC201937661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
| JP2020566701A JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Division JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024063143A JP2024063143A (ja) | 2024-05-10 |
| JP2024063143A5 true JP2024063143A5 (enExample) | 2026-02-20 |
| JP7841008B2 JP7841008B2 (ja) | 2026-04-06 |
Family
ID=68699017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269443A1 (enExample) |
| EP (1) | EP3807279B1 (enExample) |
| JP (2) | JP7778477B2 (enExample) |
| KR (1) | KR20210038848A (enExample) |
| CN (1) | CN112543758A (enExample) |
| AU (2) | AU2019277372B2 (enExample) |
| BR (1) | BR112020024332A2 (enExample) |
| CA (1) | CA3102070A1 (enExample) |
| CL (1) | CL2020003101A1 (enExample) |
| CO (1) | CO2020016582A2 (enExample) |
| IL (1) | IL279101A (enExample) |
| MX (1) | MX2020012978A (enExample) |
| WO (1) | WO2019232120A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) * | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| EP4093405A1 (en) | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| EP0722731B1 (en) * | 1994-08-05 | 2002-06-05 | Suntory Limited | Remedy for spinocerebellar degeneration |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| LT2545939T (lt) * | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| EP2562176B1 (en) * | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| CN104736539B (zh) * | 2012-05-07 | 2017-09-01 | 白鸟制药株式会社 | 墨蝶呤和四氢乳酰蝶呤的制造法 |
| EP3468534A4 (en) * | 2016-06-13 | 2020-02-05 | Meharry Medical College | MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH |
| MA46973A (fr) * | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) * | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2019
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
- 2019-05-30 US US17/059,887 patent/US20210269443A1/en active Pending
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063143A5 (enExample) | ||
| JP2021525729A5 (enExample) | ||
| JP2021527031A5 (enExample) | ||
| JP2023549226A5 (enExample) | ||
| JP2024069192A5 (enExample) | ||
| JP2008540486A (ja) | Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物 | |
| NO328340B1 (no) | Synergistisk kombinasjonsmedikament av roflumilast og salmeterol samt anvendelse derav. | |
| JP2021504313A (ja) | 慢性炎症性疾患および／または自己免疫疾患の予防または治療における使用のためのビドフルジムス（Ｖｉｄｏｆｌｕｄｉｍｕｓ）の投与レジメン | |
| JP2021505575A5 (enExample) | ||
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| US20220096475A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JP2021525746A5 (enExample) | ||
| JP2022514537A5 (enExample) | ||
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| CZ111897A3 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| JP2014513130A5 (enExample) | ||
| JPS61286326A (ja) | パ−キンソン病治療薬 | |
| JP2019531286A5 (enExample) | ||
| US20030050329A1 (en) | Synergistic combination comprising roflumilast and a PDE-3 inhibitor | |
| JP2012502105A5 (enExample) | ||
| JP2004501153A5 (enExample) | ||
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| US20070049599A1 (en) | Use of bh4 for the treatment of respiratory diseases | |
| JP2761104B2 (ja) | 脊髄小脳変性症治療剤 |